Pluristem Therapeutics Inc. and Tnuva Group jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their joint venture to develop, manufacture and commercialize cultured meat. Mr. Rosenthal is a seasoned entrepreneur and visionary leader in the agritech and food tech industries, serving until recently as venture partner and head of Israeli operations at Finistere Ventures, a pioneering global venture fund dedicated to identifying and nurturing promising agribusiness and food tech companies. He brings to his role over two decades of leadership within business, food tech, agriculture investment and sustainability, and will oversee the newventure's growth into a scaled company.

Mr. Rosenthal also served as Executive Chairman of Fresh Start, a leading global food tech incubator backed by the Israel Innovation Authority, as well as top strategic and financial players. He was previously Managing Director at Infinity Group, a $600 million growth fund, and advised the International Finance Corporation, a World Bank Group member, on global food security issues. The joint venture, which was incorporated through an agreement between Pluristem and Tnuva, has exclusive licensing rights to use Pluristem's proprietary technology and intellectual property to develop, manufacture and commercialize cultured meat.

It combines Pluristem's technological advantage in mass-scale, cost-effective cell production with Tnuva's expertise in food sector research and development (R&D), consumer marketing, and distribution.